Clinical Trials on Colorectal Liver Metastasis in China

Total 4615 results

BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Novartis Pharmaceuticals

Completed

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (RECORD-1)

Metastatic Renal Cell Carcinoma

Poland, Canada, France, Italy, Spain, United States, Germany, Australia, Netherlands, Japan
GlaxoSmithKline

Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Hepatitis C, Chronic

Puerto Rico, United States, Australia, Germany, Spain, Taiwan, Italy, Belgium, Israel, Korea, Republic of, Canada, France, Russian Federation, India, Greece, Pakistan, Slovakia, Romania, Czech Republic, Poland, Egypt, Ukraine, Brazil
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, France, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Novartis Pharmaceuticals

Active, not recruiting

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Relapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple Sclerosis

Japan
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Metastatic Non-small Cell Lung Cancer

Poland, China, United States, Argentina, Brazil, Chile, France, Guatemala, Hungary, Japan, Romania, South Africa, Spain, Taiwan, Thailand, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Bristol-Myers Squibb

Completed

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis B

Brazil, Canada, China, France, India, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Taiwan, Thailand, Turkey, United States, Colombia, Germany, Spain, Czechia, Greece, Romania, Argentina, Philippines, Singapore, Portugal
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Metastatic Non-Small Cell Lung Cancer

Poland, United States, Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Spain, Taiwan, Thailand, Turkey, United Kingdom
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Metastatic Non-Small Cell Lung Cancer

France, Spain, United States, Italy, Canada, Taiwan, Hong Kong, Japan, Turkey, Korea, Republic of, United Kingdom, Germany, Romania, Greece
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Adenocarcinoma | Recurrent Lung Non-Small Cell Carcinoma | Recurrent Lung Adenocarcinoma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

Metastatic Non-small Cell Lung Cancer

Spain, Italy, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, Germany, Argentina, United States, Brazil, India, Japan, France, Taiwan, Thailand, Turkey, Mexico, Hungary, China, Poland, Austria, South Africa, Czechia, Slo... and more
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Germany, Thailand, Brazil, Japan, Hong Kong, Greece, Switzerland, Netherlands, Romania, Hungary, Italy, Chile, Taiwan, Austria, Poland, Canada, Argentina, Turkey
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Novartis Pharmaceuticals

Completed

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States, Canada, France, Italy, Spain, Belgium, Germany, Hungary, Saudi Arabia, Netherlands, Switzerland, Australia, Austria, Poland, Sweden, United Kingdom, Thailand, Korea, Republic of, Greece, Israel, Argentina, Japan, Colo... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

Metastatic Castration-sensitive Prostate Cancer

United States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
GlaxoSmithKline

Active, not recruiting

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (B-Well 2)

Chronic Hepatitis B | Hepatitis B, Chronic

United States, Australia, Germany, Spain, Taiwan, Bulgaria, France, Thailand, Canada, Italy, Malaysia, Philippines, China, Hungary, Korea, Republic of, Romania, Greece, India, Mexico, United Kingdom, Japan, Panama, Turkey, Poland, Brazil, Argentin... and more
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
Alexion Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Wilson Disease

United States, Spain, Taiwan, France, Czechia, Hungary, Turkey, United Kingdom, Austria, Germany, Israel, Serbia, Australia, Japan, Denmark, Korea, Republic of, New Zealand, Canada, Russian Federation, Poland, Singapore, Hong Kong
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, Israel, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Spain, Sweden, Ta... and more
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastric Adenocarcinoma | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Clinical... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

NCI COVID-19 in Cancer Patients, NCCAPS Study

Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Hematopoietic and Lymphatic System Neoplasm

United States, Canada, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Anal Basaloid Squamous Cell Carcinoma

United States, Canada
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Biliary Tract Neoplasms

Canada, United States, Japan, Australia, France, Korea, Republic of
Zhujiang Hospital
National Natural Science Foundation of China

Recruiting

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Epilepsy | Chronic Kidney Diseases | Nasopharyngeal Cancer | Gastric Cancer | Pancreatic Cancer | Lung Cancer | Essential Hypertension | Acute Coronary Syndrome | Primary Aldosteronism | Liver Cancer | Subclinical hypothyroïdism

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (A-DREAM)

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States

Clinical Trials on Colorectal Liver Metastasis in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations